The antibacterial spectrum of besifloxacin, a novel fluoroquinolone recently approved for treatment of ocular infections, was studied using 2,690 clinical isolates representing 40 species. Overall, besifloxacin was the most potent agent tested against gram-positive pathogens and anaerobes and was generally equivalent to comparator fluoroquinolones in activity against most gram-negative pathogens. Besifloxacin demonstrated potent, broad-spectrum activity, which was particularly notable against gram-positive and gram-negative isolates that were resistant to other fluoroquinolones and classes of antibacterial agents. Copyright © 2009, American Society for Microbiology. All Rights Reserved.
CITATION STYLE
Haas, W., Pillar, C. M., Zurenko, G. E., Lee, J. C., Brunner, L. S., & Morris, T. W. (2009). Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. Antimicrobial Agents and Chemotherapy, 53(8), 3552–3560. https://doi.org/10.1128/AAC.00418-09
Mendeley helps you to discover research relevant for your work.